Venus Bliss launches with medical CE and FDA approval

The newest device from global medical aesthetic company Venus Concept, Venus Bliss, has received medical CE and FDA approval.

The treatment is intended for use in non-invasive lipolysis of the abdomen and flanks in individuals with a Body Mass Index (BMI) of 30 or less and is also indicated for use in temporary skin tightening, circumferential reduction, and cellulite reduction.

The platform incorporates two technologies in one system. According to the company, the 1064 nm diode laser applicators are used to treat focal fat in the abdomen and flanks through non-invasive lipolysis, resulting in fat reduction. The (MP)2 applicator combines multi-polar radiofrequency and pulsed electro-magnetic fields with the company’s VariPulse technology to complete the treatment, aiming to tighten lax skin and reduce circumference.

A study conducted by US practitioner Dr Suzanne Kilmer, involving 30 participants who received a diode laser treatment to either their flanks or abdomen, found that the majority of patients had a statistically significant reduction in adipose layer thickness when measured by ultrasound. When surveyed, 75% of participates treated said they were satisfied with their results and would recommend the treatment to a friend.

Sarah Hickey, regional director of Venus Concept UK Ltd, said, “Fat reduction is one of the fastest growing non-surgical, non-injectable, procedure categories in the medical aesthetics industry today. We are excited to introduce our fat reduction solution for the abdomen and flanks. The Venus Bliss is comfortable for patients, provides excellent results, and has little-to-no downtime. The Venus Bliss is expected to be a preferred solution for providers as there is no disposable cost per treatment, which makes the profitability per procedure more compelling for physicians.”

Share this article: